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Over the last few years, an increasing body of evidence has highlighted the critical participation of vitamin D in the regulation
of proinflammatory responses and protection against many infectious pathogens, including viruses. The activity of vitamin D is
associated with microRNAs, which are fine tuners of immune activation pathways and provide novel mechanisms to avoid the
damage that arises from excessive inflammatory responses. Severe symptoms of an ongoing dengue virus infection and disease are
strongly related to highly altered production of proinflammatory mediators, suggesting impairment in homeostatic mechanisms
that control the host’s immune response. Here, we discuss the possible implications of emerging studies anticipating the biological
effects of vitamin D and microRNAs during the inflammatory response, and we attempt to extrapolate these findings to dengue
virus infection and to their potential use for disease management strategies.
1. Introduction
Activation of innate immune cells results in the release
of proinflammatory mediators to initiate a protective local
response against invading pathogens [1]. However, overacti-
vated inflammatory activity could be detrimental since it can
cause tissue damage and even death of the host. Therefore,
negative feedback mechanisms are required to control the
duration and intensity of the inflammatory response [1, 2].
Although little is known about the molecular mechanisms
occurring during dengue virus (DENV) infection/disease,
it has been suggested that the immune response initiated
against the virus greatly contributes to pathogenesis. Indeed,
several symptoms of the disease are tightly related to imbal-
anced immune responses, particularly to high production
of proinflammatory cytokines [3, 4] suggesting an impair-
ment of homeostatic mechanisms that control inflammation.
Interestingly, vitamin D has been described as an important
modulator of immune responses to several pathogens and as
a key factor enhancing immunoregulatory mechanisms that
avoid the damage that arises from excessive inflammatory
responses [5, 6], as in dengue disease [7]. Mounting evidence
obtained from human populations and experimental in vitro
studies has suggested that this hormone can play a key
role in the immune system’s response to several viruses [8–
14], thereby becoming a potential target of intervention to
combat DENV infection and disease progression. Among
several mechanisms, vitamin D activity has been associated
with the expression of certain microRNAs (miRs) [15] that
are one of the main regulatory switches operating at the
translational level [16]. miRs constitute approximately 1% of
the human genome and their sequences can be found within
introns of other genes or can be encoded independently
and transcribed in a similar fashion to mRNAs encoded by
protein-coding genes [16]. A typicalmaturemiR of 18–23 base
pairs associates with the RNA-induced silencing complex
(RISC) and moves towards the target mRNA [17]. Once
there, the miR binds to the complementary sequence in the
3󸀠untranslated region (3󸀠UTR) of the mRNA, thereby induc-
ing gene silencing through mRNA cleavage, translational
repression, or deadenylation [16]. A single miR may directly
regulate the expression of hundreds of mRNAs at once and
several miRs can also target the same mRNA resulting in
enhanced translation inhibition [18]. Targeting of specific
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genes involved in modulation of immune response pathways
by miRs provides a finely tuned regulatory mechanism for
the restoration of the host’s resting inflammation state [19–
21]. Since the association between vitaminD andmiR activity
may play a relevant role in ongoing DENV infections, here
we provide an overview of DENV-induced inflammatory
responses and the early evidence anticipating a possible
participation of the vitamin D and miR interplay regulating
antiviral and inflammatory responses during DENV infec-
tion/disease.
2. DENV and the Immune Response
DENV is an icosahedral-enveloped viruswith a positive sense
single-stranded RNA (ssRNA) genome that belongs to the
family Flaviviridae, genus Flavivirus. There are four phylo-
genetically related but antigenically distinct viral serotypes
(DENV 1–4) able to cause the full spectrum of the disease
[22]. In addition, a sylvatic serotype (DENV-5), with no evi-
dence regarding its ability to infect humans, has been recently
reported [23]. DENV is transmitted by Aedes mosquitoes in
tropical and subtropical areas where the disease has become
a major public health threat and one of the most rapidly
spreading vector-borne diseases in theworld, with an increas-
ing incidence of 30-fold in the past 50 years [24, 25]. An
estimated 3.6 billion people live in high risk areas worldwide
and it is estimated that over 390 million cases occur every
year, of which 96 million suffer from dengue fever [26–28].
Although only a minor number of cases may progress to
the severe forms of the disease, 21.000 deaths are reported
annually [27]. Guidelines of the World Health Organization
(WHO) recognize dengue as a clinical continuum from
dengue fever (DF), a nonspecific febrile illness, to dengue
with or without warning signs that can progress to dengue
hemorrhagic fever (DHF) or dengue shock syndrome (DSS)
[3]. These severe forms of the disease are characterized by
a wide spectrum of symptoms, including the development
of vascular permeability, plasma leakage, thrombocytopenia,
focal or generalized hemorrhages, and tissue and/or organ
damage that may lead to shock and death [29, 30]. Besides
ecoepidemiology, host genetic variations, and virus virulence,
the risk factor is increased mainly by secondary infections
with different dengue serotypes, presumably through amech-
anism known as antibody-dependent immune enhancement
(ADE), whereby nonneutralizing antibodies from previous
heterotypic infections enhance virus entry via receptors for
immunoglobulins or Fc receptors (FcRs) [29, 31, 32].
Skin is the first barrier for the invading DENV and the
site where innate immunity exerts the first line of defense
[33]. Following the bite by an infected mosquito, local
tissue resident dendritic cells (DCs) and macrophages are
the main targets of the virus [34, 35]. The viral structural
E protein binds to cellular receptors, such as DC-SIGN
(Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Nonintegrin), CLEC5A (C-type lectin domain
family 5, member A), and MR (mannose receptor), allow-
ing internalization of the virus through receptor-mediated
endocytosis [22, 36–38]. Once in the cytoplasm, DENV
replication products, such as double-stranded RNA (dsRNA)
?
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Figure 1: Potential link between vitamin D and miR controlling
DENV-induced inflammatory response and antiviral activity. (1)
DENV replication products and proteins are recognized by several
PRRs whose signaling pathways promote the proinflammatory
response. (2) Vitamin D activity induces transcription of microR-
NAs and other target genes that play a critical role in the control of
inflammation-related signaling pathways and antiviral activity.
or genomic ssRNA, are sensed by several pattern recognition
receptors (PRRs) (Figure 1), including TLR3, TLR7, TLR8, the
cytosolic receptors RIG-I (Retinoic acid Inducible Gene-1),
and MDA-5 (Melanoma Differentiation-Associated protein
5) [39–43]. Subsequently, this subset of PRRs triggers the
activation of intracellular pathways, leading to the activation
of transcription factors such as interferon regulatory factors
3 and 7 (IRF3 and IRF7) and the Nuclear Factor 𝜅B (NF-
𝜅B) and the later production of type I interferons and
proinflammatory cytokines promoting an antiviral response
[44, 45]. Additionally, the local activation of natural killer
(NK) cells, neutrophils, and mast cells by the presence of the
virus inducesmore proinflammatorymediators, complement
activation, and the commitment of cellular and humoral
immune responses to clear and control viral infection [46].
2.1. Inflammation and Cytokine Storm. Although the
immune response is critical to combat and overcome
invading pathogens, it is believed that the immune response
greatly contributes to progression of dengue disease [31]. The
pathogenesis and progression to the severe forms of dengue
are still not completely understood; however, most cases are
characterized by bleeding, hemorrhage, and plasma leakage
that can progress to shock or organ failure [87, 88]. These
physiological events are preceded by a hyperpermeability
syndrome caused mainly by an imbalance between
proinflammatory and anti-inflammatory cytokines produced
in response to virus infection. The predominant proinflam-
matory mediators or “cytokine storm,” secreted mainly by T
cells, monocytes/macrophages, and endothelial cells
(Table 1), promotes endothelial dysfunction by generating
an endothelial “sieve” effect that leads to fluid and protein
leakage. Increasing evidence suggests that endothelial
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integrity and vascular permeability are affected by proinflam-
matory cytokines through the induction of apoptosis and the
modulation of tight junction molecules within endothelial
cells [47, 52, 89, 90]. In addition, it has also been reported
that these cytokines may often have synergistic effects and
may induce expression of other cytokines, generating a
positive feedback mechanism leading to further imbalanced
levels of inflammatory mediators and higher permeability
[4].
This oversustained inflammatory response may be due
to an impairment of the regulatory mechanisms that control
the duration and intensity of inflammation or cytokine pro-
duction, especially through the regulation of PRR signaling
activation [20]. Several studies have shown that alterations in
proinflammatory cytokine production during DENV infec-
tion/disease can be attributed to variations in recognition and
activation of TLR signaling, which contributes to progression
of the disease (Figure 1) [91, 92]. It was recently reported
that DENV NS1 proteins may be recognized by TLR2, TLR4,
and TLR6 enhancing the production of proinflammatory
cytokines and triggering the endothelial permeability that
leads to vascular leakage [93, 94]. Interestingly, our group has
recently shown a differential expression of TLRs in dendritic
cells (DCs) of dengue patients depending on the severity of
the disease [95]. Indeed, there was an increased expression
of TLR3 and TLR9 in DCs of patients with DF in contrast to
a poor stimulation of both receptors in DCs of patients with
DHF. Conversely, a lower expression of TLR2 in DF patients
compared to DHF patients was also observed. Additionally,
IFN-𝛼 production was also altered via TLR9, suggesting
that DENV may affect the type I IFN response through
this signaling pathway [95]. Indeed, DENV has successfully
evolved to overcome host immune responses, by efficiently
subverting the IFN pathway and inhibiting different steps
of the immune response through the expression of viral
nonstructural proteins that antagonize several molecules of
this activation pathway [96, 97]. Although DENVmay evade
immune recognition [42], cumulative data have shown that
it is sensed by both TLR3 and TLR7/8 and activates signaling
pathways upregulating IFN-𝛼/𝛽, TNF-𝛼, human defensin
5 (HD5), and human 𝛽 defensin 2 (H𝛽D2) [39–41]. In
addition, RIG-I and MDA-5 are also activated upon DENV
infection and are essential for host defense against the virus
[40]. Moreover, TLR3 controls DENV2 replication through
NF-𝜅B activation, suggesting that TLR3 agonists such as
Poly (I : C) (Polyinosinic : Polycytidylic Acid) might work as
immunomodulators of DENV infection [39]. Furthermore,
besides DENV recognition and binding, C-type lectins such
as the mannose receptor (MR) and CLEC5A may contribute
to the inflammatory responses [98–100]. CLEC5A plays
a critical role in the induction of NLRP3 inflammasome
activation during DENV infection and enhances the release
of IL-18 and IL-1𝛽 that are critical for activation ofTh17 helper
cells [99, 101].
While innate immune activation and proinflammatory
cytokine production are being investigated during the course
of DENV infections [53, 92, 102], vitamin D activity has
gained special attention due to its importance in the mod-
ulation of the innate response. An increasing number of
reports suggest that vitamin D activity is associated with the
modulation of components implicated in antiviral immune
responses and in the regulation of proinflammatory cytokine
production through the modulation of miR expression [6,
13, 15, 103]. Although there is little information from obser-
vational studies and clinical trials demonstrating the role of
vitamin D during dengue virus infection, here we postulate a
potential role of vitamin D controlling progression of dengue
disease and provide evidence of some vitamin D molecular
mechanisms in support of our hypothesis.
3. Vitamin D: Antiviral and
Anti-Inflammatory Activity
In addition to its well-known role in bone mineralization
and calcium homeostasis, vitamin D is recognized as a
pluripotent regulator of biological and immune functions
[104]. A growing body of evidence suggests that it plays a
major role during the immune system’s response to micro-
bial infection, thereby becoming a potential intervener to
control viral infections and inflammation [13, 105, 106]. The
term vitamin D refers collectively to the active form 1𝛼-
25-dihydroxyvitamin D
3
[1𝛼-25(OH)
2
D3] and the inactive
form 25-hydroxyvitamin D
3
[25(OH)D
3
] [107]. For their
transport within the serum, vitamin D compounds bind to
the vitamin D binding protein (DBP) and this complex is
recognized by megalin and cubilin (members of low-density
lipoprotein receptor family) that then internalize the complex
by invagination [108]. Intracellular trafficking of vitamin D
metabolites to specific destinations is performed bymembers
of the HSP- (Heat Shock Proteins-) 70 family [104]. In
addition, vitamin Dmetabolites are also lipophilic molecules
that can easily penetrate cell membranes and translocate
to the nucleus, where 1𝛼-25(OH)
2
D
3
binds to the vitamin
D receptor (VDR), thereby inducing heterodimerization of
VDR with an isoform of the retinoid X receptor (RXR) [109].
The VDR-RXR heterodimer binds to vitamin D response ele-
ments (VDRE) present in the promoter of hundreds of target
genes, whose products play key roles in cellular metabolism,
bone mineralization, cell growth, differentiation, and control
of inflammation (Figure 1) [104, 110, 111]. Besides VDR, other
related vitamin D metabolic components such as the hydro-
lase CYP27B1, the enzyme that catalyzes the synthesis of
active 1𝛼-25-dihydroxyvitamin D
3
from 25-hydroxyvitamin
D
3
, are present and induced in some cells of the immune
system during immune responses [112]. Thus, an increasing
number of studies have explored the relationship between
vitamin D activity and the immune system, specifically, the
mechanisms whereby vitamin D exerts its antimicrobial and
immunoregulatory activity [14, 113, 114]. Here, we highlight
those modulating antiviral and inflammatory responses.
Although controversial data have been reported, increas-
ing clinical and observational studies have provided evi-
dence supporting the protective features of vitamin D in
viral infections, especially viral respiratory infections and
HIV [13, 115, 116]. The activity of vitamin D in the innate
immune system begins at the forefront of the body’s defense
against pathogens, the skin. Regardless of global serum
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Table 2: Vitamin D-induced mechanisms/mediators associated
with antiviral activity.
Mediator/mechanism Virus Refs.
Cathelicidin (LL-37) VHS, influenza virus, HIV,retrovirus [55–59]
HBD2 HIV [60]
ROS HCV [61]
IFN response HIV, HCV [62–64]
Autophagy HIV [65, 66]
miR let-7 DENV [67, 68]
vitamin D levels, sensing of microbial pathogens via PRRs
induces upregulation of CYP27B1 and, as a consequence,
local conversion of 1,25(OH)
2
D
3
from 25(OH)D
3
, enhancing
VDR nuclear translocation and subsequent transcription
of target genes to exert antimicrobial effects [113, 117–
119]. This establishes a linkage between vitamin D status
and the intracrine and paracrine modulation of cellular
immune responses, in which VDR and CYP27B1 activity
are of central importance [117, 118, 120]. Indeed, this link is
also evidenced by studies in which pathogen susceptibility
associated with vitamin D deficiency/insufficiency levels is
reduced by correct supplementation [121, 122]. Furthermore,
some vitamin D-induced antiviral mechanisms have been
shown by preliminary reports (Table 2). Peptides such as
cathelicidins are strongly upregulated by 1,25(OH)
2
D
3
due to
its VDR response elements. In humans, active cathelicidin is
known as LL-37 and has a C-terminal cationic antimicrobial
domain that can induce bacterial membrane disruption and
inhibition of herpes simplex virus, influenza virus, and
retroviral replication, among others [55–57]. In fact, very
recent reports have suggested an association between vitamin
D and the LL-37 antiviral activity to HIV and rhinovirus
[58, 59]. Likewise, HBD-2 is also induced by 1,25(OH)
2
D
3
.
Interestingly, a correlation between VDR and HBD-2 was
found to be associated with natural resistance to HIV infec-
tion, suggesting the potential participation of vitamin D-
induced resistance to the virus [60, 106].Moreover, vitaminD
can also induce reactive oxygen species (ROS) that associates
with suppression of the replicative activity of some viruses,
such as hepatitis C virus (HCV) [61]. Although the vitamin
D-induced antiviral mechanisms are not fully elucidated and
further studies are needed to fully understand their roles,
many are possible due to the pleiotropic nature of vitamin D
and the complex transcriptional modulation of hundreds of
genes controlled by its activity.
Several studies have reported a link between VDR poly-
morphisms and severe outcomes of bronchiolitis and acute
lower respiratory tract infections (RTIs) with respiratory
syncytial virus (RSV) [105]. Indeed, vitamin D supplemen-
tation is associated with reduced RTI, vitamin D status,
and serum concentrations in children [123]. Likewise, some
vitaminD supplementation studies have reported a reduction
in cold/influenza linked to seasonal sunlight exposure and
skin pigmentation [124]. In HIV infection, associations have
also been reported between vitaminD levels with progression
Table 3: Vitamin D and miR targets associated with inflammatory
response.
Target/mediator Modulator Refs.
TLR2/4 Vitamin D/miR155.miR146 [20, 69, 70]
TNF-𝛼 Vitamin D/miR146 [70, 71]
IL-1𝛽 Vitamin D/miR155 [19, 69]
IL-6 Vitamin D/let-7e [72, 73]
MAPK Vitamin D [19]
NF-𝜅B Vitamin D/miR155, miR146 [20, 70, 74, 75]
IKK Vitamin D [76]
SOCS1 Vitamin D/miR155 [20]
TLR9 Vitamin D [77]
of the disease, survival times of HIV patients, CD4+ T cell
counts, inflammatory responses, and potential impact of
HAART (Highly Active Anti-Retroviral Therapy) treatments
[125]. Finally, similar population and ecoepidemiological
reports have associated the role of vitamin D in several viral
infections, including DENV and other flaviviruses [10–13],
not only highlighting inhibition of viral replication but also
controlling the inflammatory response and progression of the
disease.
In addition to viral control, vitamin D-induced immune
mechanisms have important effects providing potential feed-
back modulation in pathways that regulate immune acti-
vation, avoiding excessive elaboration of the inflamma-
tory responses and its potential risk for tissue homeostasis
(Table 3) [5, 6, 126]. TLRs can both affect and be affected
by VDR signaling and likewise some antimicrobial peptides
associated with TLRs have demonstrated antiviral effects
[6, 13, 127]. In this sense, and due to the interest in the
modulatory effect of vitamin D on TLR expression and
proinflammatory cytokine production, some authors have
shown that vitamin D can induce hyporesponsiveness to
PAMPs (Pathogen-Associated Molecular Patterns) by down-
regulating the expression of TLR2 and TLR4 on monocytes
that in turn have been associated with impaired production
of TNF-𝛼, suggesting a critical role of vitaminD in regulating
TLR driven inflammation [71]. Importantly, a link between
the DENV NS1 protein and activation of the inflammatory
response via TLR2 and TLR4 impacting the progression of
the disease has very recently been described [93, 128]. DENV
NS1 antigens may induce the activation of TLR2 and TLR4
inducing high secretion of proinflammatory mediators that
enhance endothelial dysfunction and permeability [46, 94,
129, 130]. Interestingly, it was reported that 1,25(OH)
2
D
3
significantly reduces the levels of TLR2/TLR4 expression
and of proinflammatory cytokines (TNF-𝛼, IL-6, IL-12p70,
and IL-1𝛽) produced by U937 cells after exposure to DENV
[72]. The same approach used in primary human monocytes
and macrophages led to similar results, consistent with data
obtained in our laboratory [19]. It has been suggested that
vitamin D may regulate proinflammatory cytokine levels
by targeting TLR activation signaling molecules (Figure 1).
Indeed, it has been reported that treatment of monocytes
with 1,25(OH)
2
D
3
regulates TLR expression via the NF-𝜅B
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pathway and reduces signaling of the mitogen-activated
protein kinases MAPKs/p38 and p42/44 [19]. One of the
most critical steps in NF-𝜅B regulation is I𝜅B𝛼 proteasomal
degradationmediated by IKK (I kappa B Kinase) that leads to
the nuclear entry of theNF-𝜅B heterodimer p65/p50 to trans-
activate gene expression, resulting in a decrease of inflam-
matory genes. Accordingly, a novel molecular mechanism
has recently been described in which 1,25(OH)
2
D
3
binding
to VDR attenuates NF-𝜅B activation by directly interacting
with the IKK𝛽 protein to block its activity and, consequently,
the NF-𝜅B-dependent inflammatory response [76]. Besides
TLR2 and TLR4, it has been shown that vitamin D can also
downregulate the intracellular TLR9 expression and, subse-
quently, lead to less secretion of IL-6 in response to TLR9
stimulation [77]. Although intracellular downregulation of
some PRRs such as TLR3, TLR7/8, and RIG-I/MDA5 may
affect the potential antiviral response induced by type I IFN,
various reports have shown that vitamin D treatment does
not affect the type I IFN-induced antiviral response against
various viruses [69, 131, 132]. In fact, it has been reported
that porcine rotavirus (PRV) infection induces CYP27B1-
dependent generation of 1,25(OH)
2
D
3
which leads to an
increased expression of TLR3 and RIG-I that consequently
enhance the type I IFN-dependent antiviral response [76].
3.1. Vitamin D and miRs: Potential Implications for Inflamma-
tion Balance. Although vitamin Dmay impact distinct path-
ways and molecules to modulate inflammatory responses,
current evidence suggests TLRs and TLR signalingmediators
as main targets by which vitamin D modulates inflammation
(Table 3) [6, 113, 133, 134]. However, a novel regulatory
vitaminDmechanism inwhich TLR signaling/activation and
miR function are associated has been recently documented,
suggesting a crucial role of vitamin D and miRs for the host
immune system homeostasis [15, 135, 136]. The participation
of miRs as general regulatory mechanisms of initiation,
propagation, and resolution of immune responses has been
widely reviewed elsewhere [21, 137, 138].Therefore, we discuss
here its potential relationship with vitamin D activity in the
control of inflammatory responses, attempting to extrapolate
these findings to DENV infection.
The ability of vitamin D to regulate miRs and their
emerging relationship have been proposed by means of
several experimental and clinical approaches; however, the
implications of their impact on inflammatory responses
have only been studied in in vitro models [15, 20, 135,
136, 139]. In patient trials with vitamin D supplementation,
significant differences in miR expression profiles have been
reported, suggesting that dietary vitamin D may also glob-
ally regulate miR levels [15]. Although several mechanisms
may be involved in regulating such a global effect, some
authors have found that chromatin states may be altered by
VDR activity, determining accessibility for binding of the
transcription and regulation of activation or inhibition of
transcription [140, 141]. This in turn could be of relevance
for canonicalVDR-VDRE-mediated transcription regulation.
In fact, VDR-induced regulation of miRs via VDRE has
been demonstrated for some miRs such as miR-182 and let-
7a whose pri-miRs (Primary miR) have multiple VDR/RXR
binding sites, suggesting that these miRs could potentially
be regulated by vitamin D metabolites [67, 142]. Moreover,
a negative feedback loop between some miRNAs and VDR
signaling has been reported. This is the case of miR-125b
whose overexpression can reduce VDR/RXR protein levels.
Since miR-125b is commonly downregulated in cancer cells,
it has been proposed that such a decrease in miR-125b may
result in the upregulation ofVDRand in increasing antitumor
effects driven by vitamin D in cancer cell models [136].
Additionally, it has been reported that VDR signaling
may attenuate TLR-mediated inflammation by enhancing a
negative feedback inhibition mechanism (Figure 1). A recent
report has shown that VDR inactivation leads to a hyper-
inflammatory response in LPS-cultured mice macrophages
through overproduction of miR-155 which in turns down-
regulates the suppressor of the cytokine signaling (SOCS)
family of proteins that are key components of the nega-
tive feedback loop regulating the intensity, duration, and
quality of cytokine signaling [2, 143, 144]. As feedback
inhibitors of inflammation, SOCS proteins are upregulated
by inflammatory cytokines, and, in turn, they block cytokine
signaling by targeting the JAK/STAT (Janus Kinase/Signal
Transducer and Activator of Transcription) pathway [2].
Evidence suggests that SOCS inhibits the proinflammatory
pathways of cytokines such as TNF-𝛼, IL-6, and IFN-𝛾
and can inhibit the LPS-induced inflammatory response by
directly blocking TLR4 signaling by targeting the IL-1R-
associated kinases (IRAK) 1 and 4 [20, 144]. Consequently,
deletion of miR-155 attenuates 1,25(OH)
2
D
3
suppression
of LPS-induced inflammation, confirming that vitamin D
stimulates SOCS1 by downregulating miR-155 [20]. Taken
together, these results highlight the importance of the VDR
pathways controlling the inflammatory response by modu-
lating miRNA-155-SOCS1 interactions. Finally, an additional
reinforcing issue that may validate the link between vitamin
D activity and miRs is the fact that 1,25(OH)
2
D
3
deficiency
has been related to reduced leukotriene synthetic capacity
in macrophages [145, 146]. Recently, it was reported that
leukotriene B4 (LTB
4
) can upregulate macrophage MyD88
(Myeloid Differentiation primary response-88) expression
by decreasing SOCS-1 stability that is associated with the
expression of proinflammatory miRs, such as miR-155, miR-
146b, and miR-125b, and TLR4 activation in macrophages
[147]. miR-146 has been also shown as a modulator of
inflammatory responsesmediated by TLR4/NF-𝜅B andTNF-
𝛼 [70]. Importantly, this miR has been found downregulated
in patients with autoimmune disorders in which low levels
of vitamin D have also been reported [148, 149].These results
suggest that vitaminD can orchestratemiR diversity involved
in TLR signaling, thereby regulating inflammatory responses
and activation of immune responses.
4. Insights into Vitamin D and
DENV Infection
Little is known about the link between DENV infection
and vitamin D; however, since severe dengue is associated
with imbalanced production of proinflammatory cytokines,
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it is very tempting to suggest that vitamin D could play an
important role in modulating the inflammatory responses
during ongoing DENV infections. Although only few studies
can illustrate a link between vitamin D activity and DENV
infection or disease, these reports have provided preliminary
epidemiological evidence supporting this novel hypothesis.
Initially, it was reported that heterozygosity in the VDR gene
was correlated with progression of dengue. It was shown in a
small Vietnamese population where dengue is endemic that
the low frequency of a dimorphic (T/t) “t” allele in the VDR
gene was associated with dengue disease severity, suggesting
a protective role of VDR activity against dengue disease
progression [12]. Variations inVDRhave also been associated
with susceptibility to osteoporosis in humans and with
reduced risk of tuberculosis and persistent hepatitis B virus
infections [150–152], highlighting the importance of VDR
variations in signaling and immune protection. Accordingly,
a study revealed the association of the “T” allele with DHF, by
showing that the “T” allele codes for a longer lengthVDR that
is the least active form of VDR. Since vitamin D is known to
suppress TNF-𝛼, it is possible that such inappropriate VDR
signaling may contribute to higher levels of inflammation,
enhancing the susceptibility to severity of the disease [10].
Although the modulatory effect of vitamin D during DENV
infection and disease has not been widely tested in human
populations, initial studies have associated the effect of
oral 25(OH)D
3
supplementation with antiviral responses,
resistance, and overcoming of the disease. Specifically, a study
reported the case of fiveDFpatients that ameliorated the signs
and symptoms of the disease, improving the overall clinical
conditions and reducing the risk of disease progression [11].
Interestingly, this may be linked to other clinical approaches
where oral supplementation with vitamin D enhanced the
antiviral response toHCV [63], another RNA virus belonging
also to the family Flaviviridae.
The potential antiviral mechanism of vitamin D against
DENV has yet not been fully explored; however, certain
reports support the proposal that vitamin D could per-
form anti-DENV effects and immunoregulatory functions
on innate immune responses [10–12]. In line with this, the
effect of vitamin D treatment of human monocytic cell
lines on DENV infection was recently reported [72]. The
authors showed that cell exposure to 1,25(OH)
2
D
3
resulted
in a significant reduction of DENV-infected cells, a variable
modulation of TLR2 andTLR4, and reduced levels of secreted
proinflammatory cytokines such as TNF-𝛼, IL-6, and IL-1𝛽
after infection [72]. The molecular mechanisms by which
vitamin D can elicit an antiviral and anti-inflammatory role
towards DENV have not been fully described, and although
we observed that monocyte-derived macrophages differenti-
ated in the presence of 1,25(OH)
2
D
3
are less susceptible to
DENV infection and express lower levels of mannose recep-
tor restricting binding of DENV to target cells (manuscript
in preparation), further studies are required to confirm
that vitamin D treatment confers both anti-inflammatory
and antiviral responses. Another interesting mechanism that
could support the antiviral activity of vitamin D is the
VDR-induced regulation of miRs via VDRE. This has been
demonstrated for some miRs, such as let-7a (Table 2), whose
pri-miR has multiple VDR/RXR binding sites that could
potentially be regulated by vitamin D [67, 142]. miR let-7a
belongs to a highly conserved family of miRs that contains
other miRs previously reported to inhibit DENV replicative
activity, such as let-7c [68]. Besides the members of the let-7
family, othermiRs have also been associatedwith suppression
of DENV infection and the inflammatory responses against
the virus, as discussed below.
4.1. MicroRNAs in DENV Infection. Viruses strictly depend
on cellular mechanisms for their replication; therefore, there
is an obligatory interaction between the virus and the host
RNA silencing machinery. Although virus-derived small
interfering RNAs may induce changes in cellular mRNA and
miR expression profiles to induce replication, cellular miRs
can also target viral sequences or induce antiviral protein
expression to inhibit viral replication and translation [153].
Indeed, during DENV infection, several cellular miRs have
been reported to have an effect on the replicative activity of
the virus and the permissiveness of the host cells. Although
some host miRs can also enhance DENV replication [81,
154], here we highlight the miRs affecting DENV replicative
activity and modulating the immune response (Table 4).
The expression levels of different miRs regulated during
DENV infection have been screened in the hepatic cell line
Huh-7. This approach identified miR let-7c as a key regulator
of the viral replicative cycle that affects viral replication and
the oxidative stress immune response through the protein
Heme Oxygenase-1 (HO-1) by activating its transcription
factor BACH1 (Basic Leucine Zipper Transcription Factor-
1) [68]. In addition, it was recently reported that, after
DENV-2 infection of the C6/36 cell line, endogenous miR-
252 is highly induced and associated with a decreased level
of viral RNA copies. This antiviral effect was explained by
the fact that miR-252 targets the DENV-2 E protein gene
sequence, downregulating its expression and therefore acting
as an antiviral regulator [78]. Although DENV can escape
the immune system by decreasing the production of type I
IFN due to DENV NS5 and NS4B activity [42, 97], DENV
infection also induces the upregulation of the cellular miR-
30e∗ that suppresses DENV replication by increasing IFN-𝛽
production.This antiviral effect of miR-30e∗ depends mainly
on NF-𝜅B activation by targeting the NF-𝜅B inhibitor I𝜅B𝛼
in DENV-permissive cells [79]. This antiviral effect induced
by signaling of type I IFN is also promoted by miR-155
that has been reported to control virus-induced immune
responses in models of infection with other members of the
Flavivirus genus such as HCV [155–157]. In this latter model,
the antiviral effect greatly depended on miR-155 targeting
SOCS-1. This observation is in accordance with a study in
which elevated expression of miR-150 in patients with DHF
was correlated with suppression of SOCS-1 expression in
monocytes [80] that in turn could be linked to the fact
that vitamin D controls inflammatory responses through
modulation of SOCS by downregulating miR-155 [20].
Although it has remained unclear whether endogenous
miRs can interfere with viral replicative activity by target-
ing DENV sequences or viral mRNAs, some experimental
approaches have shown the importance of miRs in restricting
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Table 4: Summary of miRs regulating DENV-induced inflammatory response and viral replicative activity.
miRNA Target Cell line Refs.
let-7e 3󸀠-UTR of IL-6 Human peripheral blood mononuclear cells [73]
let-7c HO-1 protein and the transcription factor BACH1 Huh-7 human hepatic cell line [68]
miR-252 DENV envelope E protein Aedes albopictus C6/36 cell line [78]
miR-30e∗ IkB𝛼 in DENV-permissive cells and IFN-𝛽 production Peripheral blood mononuclear cells and U937 andHeLa cell lines [79]
miR-150 3󸀠-UTR of SOCS-1 Peripheral blood mononuclear cells and monocytes [80]
miR-122 3󸀠-UTR of the DENV genome/mRNA BHK-21, HepG2, and Huh-7 cell lines [81]
miR-142 3󸀠-UTR of the DENV genome/mRNA Human dendritic cells and macrophages [82]
miR-133a 3󸀠-UTR of PTB; 3󸀠-UTR of the DENV genome/mRNA Mouse C2C12 cells and Vero cells [83, 84]
miR-548 5󸀠-UTR SLA (Stem Loop A) DENV U937 monocyte/macrophages [85]
miR-223 Microtubule destabilizing protein stathmin 1 (STMN-1) EA.hy926 endothelial cell line [86]
viral replication through thismechanism [85, 158–160]. Some
artificial miRs (amiRs) have been described as targeting
the highly conserved regions of the DENV-2 genome and
promoting efficient inhibition of virus replication [158].
UsingDENV subgenomic replicons carrying the specificmiR
recognition element (MRE) for miR-122 in the 3󸀠-UTR of the
DENV genome/mRNA, some authors have shown that the
liver-specific miR-122 suppresses translation and replication
of DENV by targeting this MRE sequence [81]. Likewise, the
insertion of the MRE for the hematopoietic specific miR-142
into the DENV-2 genome restricts replication of the virus
in DCs and macrophages, highlighting the importance of
this hematopoietic miR in dissemination of the virus [82]. In
addition, DENV replication is enhanced by the interaction of
the viral genome 3󸀠-UTR and the host polypyrimidine tract
binding (PTB) protein that translocates from the nucleus to
the cytoplasm facilitating DENV replication [36, 161, 162].
However, the PTB mRNA 3󸀠-UTR contains MREs that can
be targeted by miR-133a, providing a mechanism for the
downregulation of the PTB protein expression levels [163].
Moreover, in our group, we found that miR-133a contains
target sites in the 3󸀠-UTR sequence of the 4 DENV serotypes
and that overexpression of miR-133a in Vero cells was
associated with decreased DENV-2 replication activity [84].
All these data suggest a possible antiviral mechanism via
miR-133a targeting the PTB protein mRNA and the DENV
3󸀠-UTR sequence. Furthermore, we also showed that miR-
744 and miR-484 can downregulate DENV replication by
targeting the 3󸀠UTR of the DENV RNA genome [Betancur
et al., submitted]. In addition, the cellular miR-548g-3p has
been identified as displaying antiviral activity by targeting
the 5󸀠-UTR SLA (Stem Loop A) promoter of the four DENV
serotypes, thus, repressing viral replication and expression
of viral proteins, independently of interferon signaling [85].
Moreover, overexpression of miR-223 inhibited replication
of DENV in an endothelial cell-like cell line. The authors
showed that miR-223 inhibits DENV by negatively regulating
the microtubule destabilizing protein stathmin 1 (STMN-1)
that is crucial for reorganization of microtubules and later
replication of the virus. In addition, this study identified that
the transcription factors C/EBP-𝛼 and EIF2 are regulators of
miR-223 expression after DENV infection [86].
Although little is known regarding the variations in miR
expression in DENV-infected individuals, a recent study
showed the expression profile of themiRs in blood samples of
DEN-infected patients. The authors report 12 miRs that were
specifically altered upon acute dengue and 17miRs that could
potentially be associated with specific dengue-related com-
plications [164]. In addition, another profiling study reported
abundance changes in the expression of somemiRs inDENV-
infected peripheral bloodmonocytes. Importantly, let-7e was
among the miRs with the most significant regulation which,
besides anti-DENV activity, may be of crucial importance
for the modulation of inflammatory responses. Specifically,
let-7e shares matching sequences with the 3󸀠UTR mRNA of
IL-6 and CCL3, as well as of other cytokines, highlighting
a key role of miRs in immune response homeostasis during
DENV infection (Figure 1) [67, 73, 86]. Likewise, miR-223
that also shares antiviral activity against DENV has been
shown to have an important effect on the inflammatory
response by regulating IL-𝛽 and IL-6 through IKK𝛼 and
MKP-5 [86, 165, 166], stressing its potential contribution in
DENV pathogenesis control. Since a link between vitamin
D and miR expression has been established, but no reports
discuss their combined implications for DENV antiviral and
inflammatory response, we hypothesized here a vitamin D
and miR interplay that could modulate DENV pathogenesis,
opening new horizons in the therapeutic field of dengue
disease.
5. Concluding Remarks and
Future Perspectives
Severe dengue disease symptoms and DENV infection
are characterized by overproduction of proinflammatory
cytokines driven mainly by activation of several PRRs [29].
Here, we hypothesize that vitamin D may contribute to
avoiding DENV infection and disease progression, especially
through the modulation of miRs/TLRs that enhance the
antiviral activity and regulate the inflammatory response.
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Although vitamin D’s antiviral mechanism has not been
fully elucidated, it may be linked to vitamin D’s ability to
control the permissiveness of DENV target cells and the
virus-induced proinflammatory responses [72]. However, a
better understanding of these mechanisms is required to
provide interesting clues regarding DENV pathogenesis and
dengue disease treatment. Certainly, epidemiological and
experimental evidence describe an overall positive vitamin
D-related immune effect in which increased levels of vitamin
Dand variants in theVDR receptor are associatedwith reduc-
tion of viral replication, decreased risk of infection, lower
disease severity, and better outcome of the dengue symptoms
[9–12, 72]. Additionally, the emerging relationships between
vitamin D, the TLR signaling pathway, and its regulation by
miRs are beginning to gain critical importance in infectious
diseases. Indeed, as discussed above, several DENV infection
studies have started to illustrate these vitamin D regulatory
features that could be key mechanisms for the control
of virus replication and homeostasis of the inflammatory
response, thus making this hormone a special candidate for
therapeutic strategies [127]. Although most of the studies
have focused on the effects of vitamin D induced in dendritic
cells and macrophages, others have also described the same
immunoregulatory effects on other cell populations of the
immune system such as CD8+ T cells, NK cells, and B
cells [167–169] suggesting their impact not only on DENV
target cells but also at the level of cells associated with virus
clearance. All the data discussed here suggest that vitamin
D could constitute a strong potential strategy to modulate
the “cytokine storm” that occurs during ongoing DENV
infections and the progression to severe states of the disease.
Although it is important to note that such a global effect on
the inflammatory activity could weaken the host response
to other opportunistic pathogens, it has been suggested that
while vitamin D may reduce inflammatory markers during
viral infections, it also exerts protective effects against coin-
fections with other opportunistic pathogens [14, 106]. More-
over, its clinical effectiveness has been tested by improving the
overall physical condition ofDENVpatients and reducing the
progression of the disease [11]. Although incoming supple-
mentary trials are required to fully elucidate the therapeutic
relevance of vitaminD, it is evident that this hormonemay be
an excellent alternative of a natural immune-regulatory agent
capable of modulating the innate immune response against
DENV, which will provide crucial information to understand
and design strategies to treat and control progression of
dengue disease. Although further experimental studies are
required to boost the understanding of vitamin D in the
regulation of inflammation and antiviral response against
DENV infection, the information discussed above highlights
the features of vitamin D in immune regulation as an exciting
research field and as an efficient and low-cost therapeutic
procedure against DENV and possibly other viral infec-
tions.
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